LIVIVO - Search results -

Search results

Result 1 - 10 of total 33

Search options

Article ; Online: Interferon beta-1b for COVID-19.

Shalhoub, Sarah

2020 Volume 395, Issue 10238, Page(s) 1670–1671

MeSH term(s)	Adjuvants, Immunologic ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/drug therapy ; Humans ; Interferon beta-1b ; Lopinavir ; Multiple Sclerosis ; Pandemics ; Pneumonia, Viral ; Ribavirin ; Ritonavir ; SARS-CoV-2
Chemical Substances	Adjuvants, Immunologic ; Interferon beta-1b (145155-23-3) ; Lopinavir (2494G1JF75) ; Ribavirin (49717AWG6K) ; Ritonavir (O3J8G9O825)
Keywords	covid19
Language	English
Publishing date	2020-05-10
Publishing country	England
Document type	Journal Article ; Comment
ZDB-ID	3306-6
ISSN	1474-547X ; 0023-7507 ; 0140-6736
ISSN (online)	1474-547X
ISSN	0023-7507 ; 0140-6736
DOI	10.1016/S0140-6736(20)31101-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.5: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 94: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: Systemic Review and Meta-Analysis to Evaluate Therapeutic Effectiveness of Interferon Beta-1b in Hospitalized COVID-19 Patients.

Nayudu, Greeshma Sai Sree / Benny, Mamkoottathil / Thomas, Grace / Adil Khan, Maria / Basutkar, Roopa Satyanarayan

Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine

2023 Volume 48, Issue 3, Page(s) 390–400

Abstract: ... of the administration of interferon beta-1b (IFN β-1b) and standard care versus only standard care as the therapeutic ... The COVID-19 pandemic has caused havoc in the health sector. Inflammatory cytokines play ... agent for managing COVID-19 patients who are severely ill. The search was conducted in the following ...

Abstract	The COVID-19 pandemic has caused havoc in the health sector. Inflammatory cytokines play an important role in the disease condition. Existing evidence has provided certain insights into the repurposing of the drugs. This meta-analysis and systematic review aimed to explore the efficacy of the administration of interferon beta-1b (IFN β-1b) and standard care versus only standard care as the therapeutic agent for managing COVID-19 patients who are severely ill. The search was conducted in the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Scopus, and Google Scholar, which were published during the period January 1, 2020, to February 16, 2023. All the included three studies were independently assessed for eligibility. The modified data extraction form of Cochrane were used. The quality of the three included studies was assessed using the Cochrane risk of bias tool. GradePro software was used to summarize the quality grading of the primary outcome measures. The time taken for clinical improvement was (MD: -3.28 days; 95% CI: -5.65, -0.91;
Language	English
Publishing date	2023-05-30
Publishing country	India
Document type	Journal Article ; Review
ZDB-ID	2085330-0
ISSN	1998-3581 ; 0970-0218
ISSN (online)	1998-3581
ISSN	0970-0218
DOI	10.4103/ijcm.ijcm_577_22
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Interferon beta-1b for COVID-19

Shalhoub, Sarah

Lancet

Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #209919
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Interferon beta-1b for COVID-19

Shalhoub, Sarah

The Lancet

2020 Volume 395, Issue 10238, Page(s) 1670–1671

Keywords	General Medicine ; covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
ZDB-ID	3306-6
ISSN	1474-547X ; 0023-7507 ; 0140-6736
ISSN (online)	1474-547X
ISSN	0023-7507 ; 0140-6736
DOI	10.1016/s0140-6736(20)31101-6
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.5: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 94: Show issues

Order via subito

Details ▾

Article ; Online: Systemic review and meta-analysis to evaluate therapeutic effectiveness of interferon beta-1b in hospitalized COVID-19 patients

Greeshma Sai Sree Nayudu / Mamkoottathil Benny / Grace Thomas / Maria Adil Khan / Roopa Satyanarayan Basutkar

Indian Journal of Community Medicine, Vol 48, Iss 3, Pp 390-

2023 Volume 400

Abstract: ... of the administration of interferon beta-1b (IFN β-1b) and standard care versus only standard care as the therapeutic ... Interferon beta-1b is proven to reduce the duration of hospital stay, and the improved clinical status may become ... The COVID-19 pandemic has caused havoc in the health sector. Inflammatory cytokines play ...

Abstract	The COVID-19 pandemic has caused havoc in the health sector. Inflammatory cytokines play an important role in the disease condition. Existing evidence has provided certain insights into the repurposing of the drugs. This meta-analysis and systematic review aimed to explore the efficacy of the administration of interferon beta-1b (IFN β-1b) and standard care versus only standard care as the therapeutic agent for managing COVID-19 patients who are severely ill. The search was conducted in the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Scopus, and Google Scholar, which were published during the period January 1, 2020, to February 16, 2023. All the included three studies were independently assessed for eligibility. The modified data extraction form of Cochrane were used. The quality of the three included studies was assessed using the Cochrane risk of bias tool. GradePro software was used to summarize the quality grading of the primary outcome measures. The time taken for clinical improvement was (MD: -3.28 days; 95% CI: -5.65, -0.91; P value = 0.007) when treated with IFN β-1b. The duration of hospital stays (MD: -2.43 days; 95% CI: -4.45, -0.30; P value = 0.03), and need for intensive care unit (ICU) admission (RR: 0.71; 95% CI: 0.52, 0.97; P value = 0.03) was statistically significant. Interferon beta-1b is proven to reduce the duration of hospital stay, and the improved clinical status may become a cornerstone of COVID-19 treatment.
Keywords	clinical improvement ; covid-19 ; hospitalization ; hydroxychloroquine ; icu admission ; interferon ; interferon beta-1b ; lopinavir/ritonavir ; mortality ; ribavirin ; safety ; Public aspects of medicine ; RA1-1270
Subject code	610
Language	English
Publishing date	2023-01-01T00:00:00Z
Publisher	Wolters Kluwer Medknow Publications
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients.

Seyfi, Shahram / Latifi, Kayvan / Amri Male, Parviz / Sadeghi Haddad Zavareh, Mahmoud / Ezoji, Khadijeh / Mohammadnia-Afrozi, Mousa

International immunopharmacology

2021 Volume 101, Issue Pt B, Page(s) 108241

Abstract: ... interferon beta-1b) on COVID-19 inpatients.: Methods: In this study, we retrospectively evaluated the clinical ... treatment outcomes of 100 patients with COVID-19 who received IFN-β 1-a and IFN-β 1-b during their hospitalization ... This study aimed to investigate the effects of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b ...

Abstract	Background: IFNβs are known as one of the most promising drugs used for COVID-19 treatment. This study aimed to investigate the effects of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) on COVID-19 inpatients. Methods: In this study, we retrospectively evaluated the clinical treatment outcomes of 100 patients with COVID-19 who received IFN-β 1-a and IFN-β 1-b during their hospitalization period. The rate of discharge from the hospital was considered equal to the clinical improvement and then evaluated as a primary outcome. Moreover, mortality, ICU admission and length of ICU stay, frequency of intubation and use of mechanical ventilation, duration of hospitalization, laboratory factors, and medications were assessed as secondary outcomes. Results: The median discharge time of IFN-β 1a recipients was approximately equal to that of IFN-β 1-b recipients as 9 (5-10) days and 7 (5-11) days, respectively (HR = 2.43, P = 0.75). Mortality rate was also estimated as 10% among IFN-β 1-a recipients and 14% among IFN-β 1-b recipients, which was not statistically significant (p = 0.190). ICU hospitalization rate for the IFN-β 1-a recipients and IFN-β 1-b recipients was 26% and 36%, respectively. In addition, no significant difference was found between these two intervention groups in terms of ICU length of stay (1 (0-2) vs. 1 (0-4.25(, respectively,) P = 0.357). There was no significant difference between the two study groups in terms of frequency of mechanical ventilation and length of hospital stay. Conclusion: There was no significant difference between the two groups in terms of shortening the disease time, clinical improvements and other outcomes.
MeSH term(s)	Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Aged ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Antiviral Agents/therapeutic use ; Atazanavir Sulfate/therapeutic use ; COVID-19/drug therapy ; COVID-19/therapy ; Dexamethasone/therapeutic use ; Female ; Humans ; Immunization, Passive ; Inpatients ; Intensive Care Units ; Interferon beta-1a/therapeutic use ; Interferon beta-1b/therapeutic use ; Male ; Middle Aged ; Patient Discharge ; Respiration, Artificial ; Retrospective Studies ; SARS-CoV-2 ; Treatment Outcome
Chemical Substances	Antiviral Agents ; Interferon beta-1b (145155-23-3) ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Atazanavir Sulfate (4MT4VIE29P) ; Dexamethasone (7S5I7G3JQL) ; Alanine (OF5P57N2ZX) ; Interferon beta-1a (XRO4566Q4R)
Language	English
Publishing date	2021-10-15
Publishing country	Netherlands
Document type	Comparative Study ; Journal Article
ZDB-ID	2043785-7
ISSN	1878-1705 ; 1567-5769
ISSN (online)	1878-1705
ISSN	1567-5769
DOI	10.1016/j.intimp.2021.108241
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5408: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The Impact of Interferon Beta-1b Therapy on Thyroid Function and Autoimmunity Among COVID-19 Survivors.

Lui, David Tak Wai / Hung, Ivan Fan Ngai / Lee, Chi Ho / Lee, Alan Chun Hong / Tam, Anthony Raymond / Pang, Polly / Ho, Tip Yin / Cheung, Chloe Yu Yan / Fong, Carol Ho Yi / Law, Chun Yiu / To, Kelvin Kai Wang / Lam, Ching Wan / Chow, Wing Sun / Woo, Yu Cho / Lam, Karen Siu Ling / Tan, Kathryn Choon Beng

Frontiers in endocrinology

2021 Volume 12, Page(s) 746602

Abstract: Background: Some studies have indicated that interferon (IFN) may be valuable in COVID-19 ... abnormal TFTs upon reassessment in IFN-treated patients (8.1% : Conclusion: IFN for COVID-19 was ... among COVID-19 survivors.: Methods: We included consecutive adults without known thyroid disorder admitted ...

Abstract	Background: Some studies have indicated that interferon (IFN) may be valuable in COVID-19. We aimed to evaluate the impact of short-term IFN on incident thyroid dysfunction and autoimmunity among COVID-19 survivors. Methods: We included consecutive adults without known thyroid disorder admitted to Queen Mary Hospital for COVID-19 from July 2020 to January 2021 who had thyroid function tests (TFTs) and anti-thyroid antibodies measured both on admission and at three months. Results: 226 patients were included (median age 55.0 years; 49.6% men): 135 were IFN-treated. There tended to be more abnormal TFTs upon reassessment in IFN-treated patients (8.1% Conclusion: IFN for COVID-19 was associated with modest increases in anti-thyroid antibody titres, and a trend of more incident anti-TPO positivity and abnormal TFTs during convalescence. Our findings suggest that clinicians monitor the thyroid function and anti-thyroid antibodies among IFN-treated COVID-19 survivors, and call for further follow-up studies regarding the clinical significance of these changes.
MeSH term(s)	Adult ; Antibodies/analysis ; Autoimmunity/drug effects ; COVID-19/drug therapy ; COVID-19/immunology ; Cohort Studies ; Female ; Follow-Up Studies ; Humans ; Immunoglobulins, Thyroid-Stimulating/analysis ; Interferon beta-1b/adverse effects ; Interferon beta-1b/therapeutic use ; Male ; Middle Aged ; Survivors ; Thyroid Diseases/chemically induced ; Thyroid Diseases/immunology ; Thyroid Function Tests ; Thyroid Gland/drug effects ; Thyrotropin/blood ; Thyroxine/blood ; Triiodothyronine/blood
Chemical Substances	Antibodies ; Immunoglobulins, Thyroid-Stimulating ; Triiodothyronine (06LU7C9H1V) ; Interferon beta-1b (145155-23-3) ; Thyrotropin (9002-71-5) ; Thyroxine (Q51BO43MG4)
Language	English
Publishing date	2021-09-30
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2592084-4
ISSN	1664-2392
ISSN	1664-2392
DOI	10.3389/fendo.2021.746602
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial

Rahmani, H. / Davoudi-Monfared, E. / Nourian, A. / Khalili, H. / Hajizadeh, N. / Jalalabadi, N. Z. / Fazeli, M. R. / Ghazaeian, M. / Yekaninejad, M. S.

International Immunopharmacology

Abstract: In this study, efficacy and safety of interferon (IFN) beta-1b in the treatment of patients ... old) with severe COVID-19 were randomly assigned (1:1) to the IFN group or the control group Patients ... in the IFN group received IFN beta-1b (250 mcg subcutaneously every other day for two consecutive weeks ...

Abstract	In this study, efficacy and safety of interferon (IFN) beta-1b in the treatment of patients with severe COVID-19 were evaluated Among an open-label, randomized clinical trial, adult patients (=18 years old) with severe COVID-19 were randomly assigned (1:1) to the IFN group or the control group Patients in the IFN group received IFN beta-1b (250 mcg subcutaneously every other day for two consecutive weeks) along with the national protocol medications while in the control group, patients received only the national protocol medications (lopinavir/ritonavir or atazanavir/ritonavir plus hydroxychloroquine for 7-10 days) The primary outcome of the study was time to clinical improvement Secondary outcomes were in-hospital complications and 28-daymortality Between April 20 and May 20, 2020, 80 patients were enrolled and finally 33 patients in each group completed the study Time to clinical improvment in the IFN group was significantly shorter than the control group ([9(6-10) vs 11(9-15) days respectively, p = 0 002, HR = 2 30;95% CI: 1 33-3 39]) At day 14, the percentage of discharged patients was 78 79% and 54 55% in the IFN and control groups respectively (OR = 3 09;95% CI: 1 05-9 11, p = 0 03) ICU admission rate in the control group was significantly higher than the IFN group (66 66% vs 42 42%, p = 0 04) The duration of hospitalization and ICU stay were not significantly different between the groups All-cause 28-day mortality was 6 06% and 18 18% in the IFN and control groups respectively (p = 0 12) IFN beta-1b was effective in shortening the time to clinical improvement without serious adverse events in patients with severe COVID-19 Furthermore, admission in ICU and need for invasive mechanical ventilation decreased following administration of IFN beta-1b Although 28-day mortality was lower in the IFN group, further randomized clinical trials with large sample size are needed for exact estimation of survival benefit of IFN beta-1b
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #830278
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.

A Malhani, Areej / A Enani, Mushira / Saheb Sharif-Askari, Fatemeh / R Alghareeb, Mona / T Bin-Brikan, Roaa / A AlShahrani, Safar / Halwani, Rabih / Tleyjeh, Imad M

PloS one

2021 Volume 16, Issue 6, Page(s) e0252984

Abstract: ... interferon β-1b, ribavirin, and lopinavir/ritonavir) vs. FPV in non-critical hospitalized COVID-19 patients ... with non-critical COVID-19.: Methods: Single center observational study comparing IFN-based therapy ... ritonavir, ribavirin, and interferon β-1b) vs. favipiravir (FPV) in a cohort of hospitalized patients ...

Abstract	Objectives: Our study aims at comparing the efficacy and safety of IFN-based therapy (lopinavir/ritonavir, ribavirin, and interferon β-1b) vs. favipiravir (FPV) in a cohort of hospitalized patients with non-critical COVID-19. Methods: Single center observational study comparing IFN-based therapy (interferon β-1b, ribavirin, and lopinavir/ritonavir) vs. FPV in non-critical hospitalized COVID-19 patients. Allocation to either treatment group was non-random but based on changes to national treatment protocols rather than physicians' selection (quasi-experimental). We examined the association between IFN-based therapy and 28-day mortality using Cox regression model with treatment as a time-dependent covariate. Results: The study cohort included 222 patients, of whom 68 (28%) received IFN-based therapy. Antiviral therapy was started at a median of 5 days (3-6 days) from symptoms onset in the IFN group vs. 6 days (4-7 days) for the FPV group, P <0.0001. IFN-based therapy was associated with a lower 28-day mortality as compared to FPV (6 (9%) vs. 18 (12%)), adjusted hazard ratio [aHR] (95% Cl) = 0.27 (0.08-0.88)). No difference in hospitalization duration between the 2 groups, 9 (7-14) days vs. 9 (7-13) days, P = 0.732 was found. IFN treated group required less use of systemic corticosteroids (57%) as compared to FPV (77%), P = 0.005 after adjusting for disease severity and other confounders. Patients in the IFN treated group were more likely to have nausea and diarrhea as compared to FPV group (13%) vs. (3%), P = 0.013 and (18%) vs. (3%), P<0.0001, respectively. Conclusion: Early IFN-based triple therapy was associated with lower 28-days mortality as compared to FPV.
MeSH term(s)	Adult ; Aged ; Amides/therapeutic use ; Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; Drug Therapy, Combination ; Female ; Hospitalization ; Humans ; Interferon beta-1b/therapeutic use ; Lopinavir/therapeutic use ; Male ; Middle Aged ; Prospective Studies ; Pyrazines/therapeutic use ; Ribavirin/therapeutic use ; Ritonavir/therapeutic use ; SARS-CoV-2/drug effects
Chemical Substances	Amides ; Antiviral Agents ; Pyrazines ; Interferon beta-1b (145155-23-3) ; Lopinavir (2494G1JF75) ; Ribavirin (49717AWG6K) ; favipiravir (EW5GL2X7E0) ; Ritonavir (O3J8G9O825)
Language	English
Publishing date	2021-06-10
Publishing country	United States
Document type	Comparative Study ; Journal Article
ISSN	1932-6203
ISSN (online)	1932-6203
DOI	10.1371/journal.pone.0252984
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial.

Tam, Anthony Raymond / Zhang, Ricky Ruiqi / Lung, Kwok-Cheung / Liu, Raymond / Leung, Ka-Yi / Liu, Danlei / Fan, Yujing / Lu, Lu / Lam, Athene Hoi-Ying / Chung, Tom Wai-Hin / Yip, Cyril Chik-Yan / Lo, Jenny / Wu, Alan Ka-Lun / Lee, Rodney / Sin, Simon / Ng, Pauline Yeung / Chan, Wai-Ming / Shum, Hoi-Ping / Yan, Wing-Wa /

Chan, Jasper Fuk-Woo / Cheng, Vincent Chi-Chung / Lau, Chak-Sing / To, Kelvin Kai-Wang / Chan, Kwok-Hung / Yuen, Kwok-Yung / Hung, Ivan Fan-Ngai

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2022 Volume 76, Issue 3, Page(s) e216–e226

Abstract: ... COVID-19). We assessed the efficacy and safety of combined interferon beta-1b and remdesivir treatment ... interferon beta-1b 16 million units daily and remdesivir 200 mg loading on day 1 followed by 100 mg daily on day 2 ... with interferon beta-1b and remdesivir was safe and better than remdesivir only in alleviating symptoms, and ...

Abstract	Background: Early antiviral therapy was effective in the treatment of coronavirus disease 2019 (COVID-19). We assessed the efficacy and safety of combined interferon beta-1b and remdesivir treatment in hospitalized COVID-19 patients. Methods: We conducted a multicentre, prospective open-label, randomized-controlled trial involving high-risk adults hospitalized for COVID-19. Patients were randomly assigned to a 5-day interferon beta-1b 16 million units daily and remdesivir 200 mg loading on day 1 followed by 100 mg daily on day 2 to 5 (combination group), or to remdesivir only of similar regimen (control group) (1:1). The primary endpoint was the time to complete alleviation of symptoms (NEWS2 = 0). Results: Two-hundred and twelve patients were enrolled. The median days of starting treatment from symptom onset was 3 days. The median age was 65 years, and 159 patients (75%) had chronic disease. The baseline demographics were similar. There was no mortality. For the primary endpoint, the combination group was significantly quicker to NEWS2 = 0 (4 vs 6.5 days; hazard ratio [HR], 6.59; 95% confidence interval [CI], 6.1-7.09; P < .0001) when compared to the control group. For the secondary endpoints, the combination group was quicker to negative nasopharyngeal swab (NPS) viral load (VL) (6 vs 8 days; HR, 8.16; 95% CI, 7.79-8.52; P < .0001) and to develop seropositive immunoglobulin G (IgG) (8 vs 10 days; HR, 10.78; 95% CI, 9.98-11.58; P < .0001). All adverse events resolved upon follow-up. Combination group (HR, 4.1 95% CI, 1.9-8.6, P < .0001) was the most significant independent factor associated with NEWS2 = 0 on day 4. Conclusions: Early treatment with interferon beta-1b and remdesivir was safe and better than remdesivir only in alleviating symptoms, and in shortening viral shedding and hospitalization with earlier seropositivity in high-risk COVID-19 patients. Clinical trials registration: NCT04647695.
MeSH term(s)	Aged ; Humans ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; COVID-19/therapy ; COVID-19 Drug Treatment ; Interferon beta-1b/administration & dosage ; Interferon beta-1b/therapeutic use ; Prospective Studies ; SARS-CoV-2 ; Treatment Outcome
Chemical Substances	Antiviral Agents ; Interferon beta-1b (145155-23-3) ; remdesivir (3QKI37EEHE)
Language	English
Publishing date	2022-06-28
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1093/cid/ciac523
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito